Proqr Therapeutics Nv Share Price (NASDAQ: PRQR)

$2.25

▲

0.06

(2.74%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Proqr Therapeutics Nv Stock chart to analyse performance

Proqr Therapeutics Nv stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$2.16
Today's High:$2.25
$2.25
4.0%
Downside
Day's Volatility :4.0%
Upside
0.0%
52 Weeks Low:$1.07
52 Weeks High:$4.62
$2.25
52.44%
Downside
52 Weeks Volatility :76.84%
Upside
51.3%

Proqr Therapeutics Nv Stock Returns

Period	Proqr Therapeutics Nv	Sector (Health Care)	Index (Russel 2000)
3 Months	25.84%	3.6%	0.0%
6 Months	5.16%	-7.7%	0.0%
1 Year	16.67%	-12.6%	0.0%
3 Years	187.22%	9.5%	-4.7%

Proqr Therapeutics Nv Key Stats

Check Proqr Therapeutics Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.19
Open	$2.205
Today's High	$2.25
Today's Low	$2.16
Market Capitalization	$230.7M
Today's Volume	$152.5K
52 Week High	$4.62
52 Week Low	$1.07
Revenue TTM	$17.1M
EBITDA	$-41.0M
Earnings Per Share (EPS)	$-0.47
Profit Margin	-231.45%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-79.47%

Stock Returns calculator for Proqr Therapeutics Nv Stock including INR - Dollar returns

The Proqr Therapeutics Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Proqr Therapeutics Nv investment value today

Current value as on today

₹1,22,472

Returns

₹22,472

(+22.47%)

Returns from Proqr Therapeutics Nv Stock

₹17,188 (+17.19%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Proqr Therapeutics Nv Stock

20%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Proqr Therapeutics Nv Stock from India on INDmoney has increased by 20% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Proqr Therapeutics Nv

Name
Holdings %
Name
Holdings %
Adage Capital Partners Gp LLC
7.69%
Privium Fund Management B.V.
4.74%
Affinity Asset Advisors, LLC
3.12%
Sio Capital Management, LLC
1.97%
Millennium Management LLC
1.97%
Aberdeen Group PLC
1.76%

Analyst Recommendation on Proqr Therapeutics Nv Stock

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Proqr Therapeutics Nv(by analysts ranked 0 to 5 stars)

Proqr Therapeutics Nv Share Price Target

What analysts predicted

Upside of 294.44%

Target:

$8.88

Current:

$2.25

Proqr Therapeutics Nv share price target is $8.88, a slight Upside of 294.44% compared to current price of $2.25 as per analysts' prediction.

Proqr Therapeutics Nv Stock Insights

Price Movement
In the last 3 years, PRQR stock has moved up by 189.7%
Decreasing Revenue
Revenue is down for the last 2 quarters, 4.51M → 3.81M (in $), with an average decrease of 15.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 5 quarters, -2.69M → -12.17M (in $), with an average decrease of 61.3% per quarter
PRQR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 59.0%
Price to Sales
ForPRQR every $1 of sales, investors are willing to pay $12.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Proqr Therapeutics Nv Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$2.1M	↓ 60.88%
Net Income	$-63.1M	↑ 53.81%
Net Profit Margin	-2.9K%	↓ 2188.95%

	FY20	Y/Y Change
Revenue	$295.6K	↓ 87.43%
Net Income	$-56.7M	↓ 17.86%
Net Profit Margin	-19.2K%	↓ 16247.08%

	FY21	Y/Y Change
Revenue	$1.5M	↑ 457.2%
Net Income	$-69.7M	↑ 32.32%
Net Profit Margin	-4.6K%	↑ 14627.33%

	FY22	Y/Y Change
Revenue	$4.3M	↑ 198.15%
Net Income	$-68.7M	↑ 5.21%
Net Profit Margin	-1.6K%	↑ 2947.98%

	FY23	Y/Y Change
Revenue	$7.1M	↑ 61.36%
Net Income	$-30.7M	↓ 56.67%
Net Profit Margin	-431.67%	↑ 1175.74%

	FY24	Y/Y Change
Revenue	$19.8M	↑ 190.22%
Net Income	$-29.0M	↓ 1.27%
Net Profit Margin	-146.86%	↑ 284.81%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$4.9M	↑ 39.89%
Net Income	$-8.4M	↑ 44.19%
Net Profit Margin	-172.09%	↓ 5.13%

	Q2 FY24	Q/Q Change
Revenue	$6.8M	↑ 41.57%
Net Income	$-2.9M	↓ 65.05%
Net Profit Margin	-42.48%	↑ 129.61%

	Q3 FY24	Q/Q Change
Revenue	$4.3M	↓ 39.36%
Net Income	$-9.0M	↑ 201.19%
Net Profit Margin	-210.98%	↓ 168.5%

	Q4 FY24	Q/Q Change
Revenue	$4.5M	↑ 12.07%
Net Income	$-9.7M	↑ 14.76%
Net Profit Margin	-216.04%	↓ 5.06%

	Q1 FY25	Q/Q Change
Revenue	$4.9M	↑ 4.92%
Net Income	$-10.9M	↑ 8.32%
Net Profit Margin	-223.04%	↓ 7.0%

	Q2 FY25	Q/Q Change
Revenue	$3.8M	↓ 15.53%
Net Income	$-12.2M	↑ 20.84%
Net Profit Margin	-319.07%	↓ 96.03%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-127.7M	↓ 3003.1%

	FY20	Y/Y Change
Profit	$-2.7M	↓ 98.09%

	FY21	Y/Y Change
Profit	$1.5M	↓ 161.71%

	FY22	Y/Y Change
Profit	$1.7M	↑ 15.32%

	FY23	Y/Y Change
Profit	$7.0M	↑ 308.64%

	FY24	Y/Y Change
Profit	$19.8M	↑ 196.29%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$4.1M	↑ 18.17%

	Q2 FY24	Q/Q Change
Profit	$6.0M	↑ 48.69%

	Q3 FY24	Q/Q Change
Profit	$4.3M	↓ 31.65%

	Q4 FY24	Q/Q Change
Profit	$4.5M	↑ 12.07%

	Q1 FY25	Q/Q Change
Profit	$4.9M	↑ 4.92%

	Q2 FY25	Q/Q Change
Profit	$3.8M	↓ 15.53%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-48.9M	↑ 43.31%
Investing Cash Flow	$-644.5K	↑ 85.9%
Financing Cash Flow	$55.8M	↓ 43.37%

	FY20	Y/Y Change
Operating Cash Flow	$-57.2M	↑ 7.03%
Investing Cash Flow	$-1.1M	↑ 59.31%
Financing Cash Flow	$17.6M	↓ 71.11%

	FY21	Y/Y Change
Operating Cash Flow	$-29.4M	↓ 44.73%
Investing Cash Flow	$-480.4K	↓ 54.0%
Financing Cash Flow	$154.7M	↑ 843.67%

	FY22	Y/Y Change
Operating Cash Flow	$-72.5M	↑ 163.37%
Investing Cash Flow	$-742.9K	↑ 65.18%
Financing Cash Flow	$-32.7M	↓ 122.58%

	FY23	Y/Y Change
Operating Cash Flow	$23.5M	↓ 131.45%
Investing Cash Flow	$4.7M	↓ 709.4%
Financing Cash Flow	$-2.5M	↓ 92.64%

	FY24	Y/Y Change
Operating Cash Flow	$-38.1M	↓ 268.89%
Investing Cash Flow	$-4.3M	↓ 195.21%
Financing Cash Flow	$73.5M	↓ 3189.05%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-16.4M	↑ 184.33%
Investing Cash Flow	$-19.3M	↓ 454.64%
Financing Cash Flow	$-455.4K	↓ 61.63%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-6.7M	↓ 58.66%
Investing Cash Flow	$-287.3K	↓ 98.49%
Financing Cash Flow	$-303.4K	↓ 32.7%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-6.3M	↓ 9.57%
Investing Cash Flow	$18.6M	↓ 6359.93%
Financing Cash Flow	$-503.0K	↑ 60.64%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-9.8M	↑ 65.25%
Investing Cash Flow	$-2.9M	↓ 116.68%
Financing Cash Flow	$74.7M	↓ 15868.21%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-17.1M	↑ 69.0%
Investing Cash Flow	$-242.2K	↓ 91.97%
Financing Cash Flow	$-540.7K	↓ 100.7%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-11.4M	↓ 27.83%
Investing Cash Flow	$-101.0K	↓ 54.91%
Financing Cash Flow	$-293.0K	↓ 41.4%

Proqr Therapeutics Nv Technicals Summary

Sell

Neutral

Buy

Proqr Therapeutics Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Proqr Therapeutics Nv Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Proqr Therapeutics Nv	7.69%	5.16%	16.67%	187.22%	-62.1%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Proqr Therapeutics Nv	NA	NA	0.0	-0.47	-0.79	-0.2	NA	0.64
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Proqr Therapeutics Nv	Buy	$230.7M	-62.1%	NA	-231.45%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Proqr Therapeutics Nv

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Organization	Proqr Therapeutics Nv
Employees	166
CEO	Mr. Daniel Anton de Boer
Industry	Health Technology

Key Management of Proqr Therapeutics Nv

Name	Title
Mr. Daniel Anton de Boer	Founder, CEO & Member of Management Board
Dr. Gerard Platenburg Ph.D.	Co-Founder, Chief Scientific Officer & Member of Management Board
Dr. Domenico Valerio Ph.D.	Founder & Independent Member of Supervisory Board
Mr. Dennis Hom	Chief Financial Officer
Ms. Sheila Sponselee	Chief People & Operations Officer
Ms. Sarah Cue Kiely	Vice President of Investor Relations & Corporate Communications
Dr. Cristina Lopez Lopez M.D., Ph.D.	Chief Medical Officer
Ms. Sandra van der Kolk	Junior Financial Controller

Important FAQs about investing in PRQR Stock from India :

What is Proqr Therapeutics Nv share price today?

Proqr Therapeutics Nv share price today is $2.25 as on August 30, 2025 at 1:29 am IST at the close of the market. Proqr Therapeutics Nv share today touched a day high of $2.25 and a low of $2.16.

What is the 52 week high and 52 week low for Proqr Therapeutics Nv share?

Proqr Therapeutics Nv share touched a 52 week high of $4.62 and a 52 week low of $1.07. Proqr Therapeutics Nv stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $2.25, lower by 51.3% versus the 52 week high.

How to invest in Proqr Therapeutics Nv Stock (PRQR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Proqr Therapeutics Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Proqr Therapeutics Nv Shares that will get you 0.6667 shares as per Proqr Therapeutics Nv share price of $2.25 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Proqr Therapeutics Nv Stock (PRQR) from India?

Indian investors can start investing in Proqr Therapeutics Nv (PRQR) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Proqr Therapeutics Nv stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Proqr Therapeutics Nv share’s latest price of $2.25 as on August 30, 2025 at 1:29 am IST, you will get 4.4444 shares of Proqr Therapeutics Nv. Learn more about fractional shares .

What are the returns that Proqr Therapeutics Nv has given to Indian investors in the last 5 years?

Proqr Therapeutics Nv stock has given -62.1% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?